(ABVX) Abivax American Depositary - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 9.004m USD | Total Return: 1916.4% in 12m
Avg Turnover: 101M
Warnings
Interest Coverage Ratio -10.2 is critical
Altman Z'' -10.90 < 1.0 - financial distress zone
Volatile
Tailwinds
Leader
Abivax SA is a clinical-stage biotechnology firm based in France, specializing in therapies for chronic inflammatory diseases. The company’s primary focus is the development of obefazimod, a drug candidate currently undergoing Phase 3 clinical trials for ulcerative colitis and Phase 2b trials for Crohns disease.
The company operates within the immunology sector, where drug development typically requires high capital expenditure and multi-year regulatory approval processes. Abivax utilizes a business model centered on targeting the body’s natural regulatory mechanisms to achieve long-term immune system stabilization.
Investors tracking clinical milestones may find additional data points on ValueRay useful for deeper analysis. Because the company’s valuation is heavily tied to the success of its lead candidate, monitoring trial progression remains a critical factor for risk assessment.
- Obefazimod Phase 3 clinical trial results for ulcerative colitis determine valuation
- Regulatory approval timeline for Crohns disease Phase 2b impacts investor confidence
- R&D expenditure and cash runway influence future equity financing needs
- Strategic partnerships or licensing agreements provide non-dilutive capital and validation
- Competitive landscape in chronic inflammatory disease market affects long-term peak sales
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.42 > 0.02 and ΔFCF/TA 47.38 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.42 > 3% & CFO -242.5m > Net Income -528.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (69.5m) vs 12m ago 10.06% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 5.26%; Δ -5.26% > 0%) |
| Interest Coverage Ratio: -10.20 > 6 (EBITDA TTM -367.6m / Interest Expense TTM 36.1m) |
| A: 0.84 (Total Current Assets 551.0m - Total Current Liabilities 63.0m) / Total Assets 584.1m |
| B: -1.26 (Retained Earnings -738.2m / Total Assets 584.1m) |
| C: -0.93 (EBIT TTM -368.6m / Avg Total Assets 394.7m) |
| D: -5.69 (Book Value of Equity -735.1m / Total Liabilities 129.1m) |
| Altman-Z'' = -10.90 = D |
As of May 24, 2026, the stock is trading at USD 121.99 with a total of 1,170,900 shares traded.
Over the past week, the price has changed by +6.51%,
over one month by +5.17%,
over three months by -8.22% and
over the past year by +1916.36%.
Abivax American Depositary has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy ABVX.
- StrongBuy: 4
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 155.2 | 27.2% |
P/S = 1970.1343
P/B = 18.2007
Revenue TTM = 0.0 EUR
EBIT TTM = -368.6m EUR
EBITDA TTM = -367.6m EUR
Long Term Debt = 15.9m EUR (from longTermDebt, two quarters ago)
Short Term Debt = 1.30m EUR (from shortTermDebt, last quarter)
Debt = 33.9m EUR (from shortLongTermDebtTotal, last quarter) + Leases 1.86m
Net Debt = -496.2m EUR (calculated: Debt 33.9m - CCE 530.2m)
Enterprise Value = 7.24b EUR (7.74b + Debt 33.9m - CCE 530.2m)
Interest Coverage Ratio = -10.20 (Ebit TTM -368.6m / Interest Expense TTM 36.1m)
EV/FCF = -29.85x (Enterprise Value 7.24b / FCF TTM -242.6m)
FCF Yield = -3.35% (FCF TTM -242.6m / Enterprise Value 7.24b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 1.03m) / Revenue TTM)
Tobins Q-Ratio = 12.40 (Enterprise Value 7.24b / Total Assets 584.1m)
Interest Expense / Debt = 106.5% (Interest Expense 36.1m / Debt 33.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -291.2m (EBIT -368.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.75 (Total Current Assets 551.0m / Total Current Liabilities 63.0m)
Debt / Equity = 0.07 (Debt 33.9m / totalStockholderEquity, last quarter 455.0m)
Debt / EBITDA = 1.35 (negative EBITDA) (Net Debt -496.2m / EBITDA -367.6m)
Debt / FCF = 2.05 (negative FCF - burning cash) (Net Debt -496.2m / FCF TTM -242.6m)
Total Stockholder Equity = 227.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -133.9% (out of range, set to none)
RoE = -54.72% (Net Income TTM -528.6m / Total Stockholder Equity 966.0m)
RoCE = -37.54% (EBIT -368.6m / Capital Employed (Equity 966.0m + L.T.Debt 15.9m))
RoIC = -56.79% (negative operating profit) (NOPAT -291.2m / Invested Capital 512.8m)
WACC = 17.53% (E(7.74b)/V(7.77b) * Re(17.61%) + (debt cost/tax rate unavailable))
Discount Rate = 17.61% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 91.11 | Cagr: 88.13%
[DCF] Fair Price = unknown (Cash Flow -242.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.19 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -2.60 | # QB: -1
EPS current Quarter (2026-06-30): EPS=-0.74 | Chg30d=-0.48% | Revisions=-20% | Analysts=2
EPS current Year (2026-12-31): EPS=-3.65 | Chg30d=-0.44% | Revisions=-20% | GrowthEPS=+34.8% | GrowthRev=-43.9%
EPS next Year (2027-12-31): EPS=-2.86 | Chg30d=-0.57% | Revisions=-20% | GrowthEPS=+21.6% | GrowthRev=+4470.2%
[Analyst] Revisions Ratio: -20%